Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 555 clinical trials
featured
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

lung carcinoma
epidermal growth factor receptor
erlotinib
lung cancer
epidermal growth factor
  • 100 views
  • 23 Nov, 2020
  • 1 location
featured
A PHASE 3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

="text-decoration: underline;">Primary: - To assess the change from baseline in estimated glomerular filtration rate (eGFR) at Week 52 following a 4-week drug

  • 63 views
  • 23 Nov, 2020
  • 2 locations
featured
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

lung carcinoma
cancer
lung cancer
  • 92 views
  • 23 Nov, 2020
  • 1 location
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

  • 268 views
  • 15 Dec, 2020
  • 16 locations
featured
Advanced EGFR-positive Solid Tumor Malignancies

People with tumors are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 201 views
  • 08 Jul, 2020
  • 1 location
featured
EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including

lung carcinoma
lung cancer
EGFR
ovarian cancer
carcinoma
  • 786 views
  • 24 Nov, 2020
  • 1 location
featured
BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

  • 988 views
  • 23 Nov, 2020
  • 1 location
featured
LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

alopecia
lung carcinoma
squamous cell carcinoma
pembrolizumab
lung cancer
  • 538 views
  • 24 Nov, 2020
  • 1 location
featured
ALN-CC5-005: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy

This is a multicenter, double-blind, placebo-controlled study comprised of three periods  The first period of the study is an observational 14-week run-in period during which patients’ blood pressure, kidney function, degree of hematuria, and proteinuria will be measured. Patients will not receive study drug (cemdisiran or placebo) during this time. …

  • 99 views
  • 23 Nov, 2020
  • 2 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the

carboplatin
gilbert's syndrome
osimertinib
EGFR
lung metastases
  • 0 views
  • 17 Jan, 2021
  • 11 locations